378 related articles for article (PubMed ID: 21518598)
41. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
[TBL] [Abstract][Full Text] [Related]
42. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
43. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction.
Lucreziotti S; Centola M; Salerno-Uriarte D; Ponticelli G; Battezzati PM; Castini D; Sponzilli C; Lombardi F
Int J Cardiol; 2014 Jun; 174(1):37-42. PubMed ID: 24698233
[TBL] [Abstract][Full Text] [Related]
44. Sodium bicarbonate versus normal saline for protection against contrast nephropathy.
Budhiraja P; Chen Z; Popovtzer M
Ren Fail; 2009; 31(2):118-23. PubMed ID: 19212908
[TBL] [Abstract][Full Text] [Related]
45. Incidence, predictors, and outcomes of post-percutaneous coronary intervention nephropathy in patients with diabetes mellitus and normal baseline serum creatinine levels.
Roy P; Raya V; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jun; 101(11):1544-9. PubMed ID: 18489931
[TBL] [Abstract][Full Text] [Related]
46. [Contrast-induced nephropathy in coronarography of patients with type 2 diabetes mellitus: risk factors, prognostic significance, prophylactic approaches].
Shamkhalova MSh; Zaĭtseva NV; Kurumova KO; Shestakova MV; Deev AD; Matskeplishvili ST; Tugeeva EF; Buziashvili IuI
Ter Arkh; 2009; 81(8):36-42. PubMed ID: 19799198
[TBL] [Abstract][Full Text] [Related]
47. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
[TBL] [Abstract][Full Text] [Related]
48. Impact of minimum contrast media volumes during elective percutaneous coronary intervention for prevention of contrast-induced nephropathy in patients with stable coronary artery disease.
Ebisawa S; Kurita T; Tanaka N; Nasu K; Kimura M; Ito T; Kinoshita Y; Tsuchikane E; Terashima M; Suzuki T
Cardiovasc Interv Ther; 2016 Jan; 31(1):13-20. PubMed ID: 26001976
[TBL] [Abstract][Full Text] [Related]
49. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
50. Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography.
Madsen TE; Pearson RR; Muhlestein JB; Lappé DL; Bair TL; Horne BD; Anderson JL;
Crit Pathw Cardiol; 2009 Dec; 8(4):167-71. PubMed ID: 19952552
[TBL] [Abstract][Full Text] [Related]
51. Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions.
Chong E; Poh KK; Liang S; Soon CY; Tan HC
J Interv Cardiol; 2010 Oct; 23(5):451-9. PubMed ID: 20796168
[TBL] [Abstract][Full Text] [Related]
52. The ratio of contrast volume to glomerular filtration rate predicts in-hospital and six-month mortality in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
Çiçek G; Bozbay M; Açıkgöz SK; Altay S; Uğur M; Köroğlu B; Uyarel H
Cardiol J; 2015; 22(1):101-7. PubMed ID: 24671903
[TBL] [Abstract][Full Text] [Related]
53. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
[TBL] [Abstract][Full Text] [Related]
54. Female sex and risk of contrast nephropathy after percutaneous coronary intervention.
Mueller C; Buerkle G; Perruchoud AP; Buettner HJ
Can J Cardiol; 2004 Apr; 20(5):505-9. PubMed ID: 15100752
[TBL] [Abstract][Full Text] [Related]
55. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
[TBL] [Abstract][Full Text] [Related]
56. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Patti G; Nusca A; Chello M; Pasceri V; D'Ambrosio A; Vetrovec GW; Di Sciascio G
Am J Cardiol; 2008 Feb; 101(3):279-85. PubMed ID: 18237585
[TBL] [Abstract][Full Text] [Related]
57. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Zhao L; Wang L; Zhang Y
J Invasive Cardiol; 2009 Oct; 21(10):493-8. PubMed ID: 19805833
[TBL] [Abstract][Full Text] [Related]
58. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
59. Post-coronarography application of continuous veno-venous hemofiltration in the prevention of contrast nephropathy in patients with complex multisystem deficiency.
La Manna G; Pancaldi L; Dalmastri V; Cuna V; Capecchi A; Comai G; Persici E; Bacchi G; Cianciolo G; Lombardi A; Marrozzini C; Colì L; Stefoni S
In Vivo; 2008; 22(1):123-9. PubMed ID: 18396794
[TBL] [Abstract][Full Text] [Related]
60. [Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention].
He YT; Tan N; Liu YH; Chen SQ; Liu Y; Huang SJ; Yang DH; Ye P; Ran P
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 May; 41(5):394-8. PubMed ID: 24021122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
